Bio-Techne management check
TECH · Health Care · Life Sciences Tools & Services · CEO Kim Kelderman
Filings as of
Closest peers in Life Sciences Tools & Services
- 101WATWaters Corporation76
- 108MTDMettler Toledo76
- 151DHRDanaher Corporation72
- 168IQVIQVIA71
- 307TMOThermo Fisher Scientific61
- 375CRLCharles River Laboratories56
- 386AAgilent Technologies55
- 443ILMNIllumina, Inc.47
- 453TECHBio-Techne45
The seven checks
- FlagTrailed its chosen peers
Have owners done well?
What $100 became since fiscal 2021
2130thDetail
$100 invested at the start of fiscal 2021 grew to $79, against $104 for the peer group the company picked itself.
- GoodPay rose and fell with returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
9067thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of 0.79 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Flag11.1% of net income
What does the CEO cost owners?
$8.2m pay · $73.4m net income, FY2025
016thDetail
$8.2m of reported pay in fiscal 2025, against $73.4m of net income.
- WatchCEO stake ≈ 0.7 years of pay
Do they own the stock?
80,509 shares ≈ $5.8m
6 mo: ▲ $0 bought · ▼ $0 sold
2826thDetail
The CEO holds 80,509 shares, directly or through trusts (unvested awards not counted): about 0.7 years of pay. No open-market insider buying or selling in the last six months.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares −0.7% a year; flagged above +2%
Stock pay 3.3% of revenue
5848thDetail
Diluted shares changed -0.7% a year over the last three fiscal years. Stock-based pay was 3.3% of revenue in the latest year.
- Watch2 CEOs in the pay table
Is leadership stable?
7 filings under 8-K 5.02 in 3 years
CEOs: Mr. Kummeth, Mr. Kelderman
5025thDetail
CEOs in the pay table: Mr. Kummeth, Mr. Kelderman. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- WatchAn annual report was amended
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 110-K amended
7015thDetail
No restatements, auditor changes or late filings since 2021. 1 amended annual report.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed September 19, 2025.
Pay tied most to organic revenue
Other key measuresOrganic RevenueAdjusted Net Income
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Mr. Kelderman | $8.2m | $2.5m | $3.7m | $79 | $104 | $73.4m |
| 2024 | Mr. Kelderman, Mr. Kummeth | $6.8m | $4.8m | $3.3m | $110 | $131 | $168.1m |
| 2023 | Mr. Kummeth | $30.6m | $4.7m | $2.3m | $125 | $127 | $285.4m |
| 2022 | Mr. Kummeth | $15.4m | $0 | $3.2m | $132 | $130 | $263.1m |
| 2021 | Mr. Kummeth | $15.9m | $105.7m | $5.0m | $171 | $148 | $139.6m |
Insiders and the CEO's stakeQuiet
- Chief Executive Officer
- Kim Kelderman
- Shares held
- 80,509
- At that filing's price
- ≈ $5.8m
- Latest Form 4
- Nov 1, 2026
No open-market insider buying or selling in the last six months.
Open-market trades by officers and directors since May 21, 2026.
Leadership and governance on file
All 12 filings
- Oct 28, 2026Annual report amended10-K/A
- Jun 26, 2026Leadership change8-K 5.02
- Feb 11, 2026Leadership change8-K 5.02
- Mar 4, 2025Leadership change8-K 5.02
- Feb 5, 2025Leadership change8-K 5.02
- Nov 5, 2024Leadership change8-K 5.02
- Apr 30, 2024Leadership change8-K 5.02
- Jan 8, 2024Leadership change8-K 5.02
- Oct 19, 2023Leadership change8-K 5.02
- Jan 31, 2023Leadership change8-K 5.02
- Aug 5, 2022Leadership change8-K 5.02
- Dec 22, 2021Leadership change8-K 5.02
Latest shareholder vote results: Sep 23, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $830.4m returned to owners in buybacks and dividends, 88% of net income, and $209.3m of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $931.0m | $1.1bn | $1.1bn | $1.2bn | $1.2bn |
| Net income | $140.4m | $272.1m | $285.3m | $168.1m | $73.4m |
| Stock-based pay | $49.0m | $42.2m | $39.2m | $38.0m | $40.8m |
| Buybacks | $43.2m | $160.9m | $19.6m | $80.0m | $275.7m |
| Dividends | $49.6m | $50.2m | $50.3m | $50.4m | $50.4m |
| Diluted shares | 162m | 164m | 162m | 161m | 160m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.